Ticker Launch
Sign inTry it free

SPAC · Merger completed

TenX Keane Acquisition

Business combination with Citius Pharmaceuticals' oncology business

TenX Keane Acquisition is a blank-check company (SPAC) that raised $60M in its initial public offering on Oct 14, 2022, listing on Nasdaq Global Market. It completed its business combination with Citius Pharmaceuticals' oncology business on Aug 12, 2024; the combined company is Citius Oncology, Inc. (CTOR). Maxim Group led the IPO. Ogier advised the SPAC and Lucosky Brookman advised the underwriters on the IPO.

Citius Oncology is a late-stage pharmaceutical company focused on developing and commercializing targeted oncology therapies. It is the oncology business of Citius Pharmaceuticals and the subject of a business combination.

Status
Merger completed
IPO date
Oct 14, 2022
IPO size
$60M
IPO exchange
Nasdaq Global Market
Target
Citius Pharmaceuticals' oncology business (SpinCo)
Announced
Oct 24, 2023
Closed
Aug 12, 2024
Combined company
Citius Oncology, Inc. (CTOR)
IPO underwriters
Maxim Group
SPAC counsel (IPO)
Ogier
Underwriters' counsel (IPO)
Lucosky Brookman

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2024